Peter S Ganly

Summary

Country: New Zealand

Publications

  1. ncbi Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia
    Peter Ganly
    Cancer Genetics Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
    Leuk Lymphoma 45:1-10. 2004
  2. ncbi Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera
    Peter Ganly
    Cancer Genetics Research Group, Christchurch School of Medicine and Health Science, Christchurch, New Zealand
    Am J Hematol 82:80-2. 2007
  3. ncbi Written advice can provide a safe and acceptable alternative to new patient assessment for selected referrals to haematologists
    Peter S Ganly
    Department of Haematology, Canterbury Health Laboratories and Christchurch Hospital, Christchurch, New Zealand
    Med J Aust 188:9-12. 2008
  4. ncbi Successful treatment of transplant-associated microangiopathy with rituximab
    Helen Marr
    Department of Haematology, Christchurch Hospital and Canterbury Health Laboratories, PO Box 151, Christchurch 8140, New Zealand
    N Z Med J 122:72-4. 2009
  5. ncbi A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia
    Logan C Walker
    Cancer Genetics Research Group, Christchurch School of Medicine, Christchurch, New Zealand
    Br J Haematol 117:878-81. 2002
  6. ncbi Fibrinogen Hillsborough: a novel gammaGly309Asp dysfibrinogen with impaired clotting
    Jennifer L Mullin
    Molecular Pathology Laboratory, Canterbury Health Laboratories, Christchurch Hospital, Christchurch, New Zealand
    Blood 99:3597-601. 2002

Collaborators

  • S O Brennan
  • Helen Marr
  • Logan C Walker
  • Jennifer L Mullin
  • Mark Smith
  • Hilda Mangos
  • Eileen Merriman
  • Catherine Stoddart
  • Emma Jane McDonald
  • Donald H Macdonald
  • Christine M Morris
  • Jane Stevens
  • Peter M George
  • David Heaton
  • Hamish Campbell
  • Ruth Spearing
  • Rob Corbett

Detail Information

Publications6

  1. ncbi Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia
    Peter Ganly
    Cancer Genetics Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
    Leuk Lymphoma 45:1-10. 2004
    ....
  2. ncbi Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera
    Peter Ganly
    Cancer Genetics Research Group, Christchurch School of Medicine and Health Science, Christchurch, New Zealand
    Am J Hematol 82:80-2. 2007
    ..Early screening of suspected PV patients for JAK2(V617F) rapidly identifies nearly all those with PV without invasive or less specific conventional investigations...
  3. ncbi Written advice can provide a safe and acceptable alternative to new patient assessment for selected referrals to haematologists
    Peter S Ganly
    Department of Haematology, Canterbury Health Laboratories and Christchurch Hospital, Christchurch, New Zealand
    Med J Aust 188:9-12. 2008
    ..To measure the safety and acceptability of providing written advice (WA) for selected patients referred to a haematology service, as an alternative to inpatient or outpatient assessment...
  4. ncbi Successful treatment of transplant-associated microangiopathy with rituximab
    Helen Marr
    Department of Haematology, Christchurch Hospital and Canterbury Health Laboratories, PO Box 151, Christchurch 8140, New Zealand
    N Z Med J 122:72-4. 2009
    ..We describe a patient with severe manifestations of this disorder who recovered promptly following treatment with rituximab, an anti-CD20 antibody...
  5. ncbi A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia
    Logan C Walker
    Cancer Genetics Research Group, Christchurch School of Medicine, Christchurch, New Zealand
    Br J Haematol 117:878-81. 2002
    ..We have identified a unique point mutation of the RUNX1 gene (A107P) in members of a family with autosomal dominant inheritance of thrombocytopenia. One member has developed acute myeloid leukaemia (AML)...
  6. ncbi Fibrinogen Hillsborough: a novel gammaGly309Asp dysfibrinogen with impaired clotting
    Jennifer L Mullin
    Molecular Pathology Laboratory, Canterbury Health Laboratories, Christchurch Hospital, Christchurch, New Zealand
    Blood 99:3597-601. 2002
    ....